Avoro Capital Advisors LLC: XENON PHARMACEUTICALS INC (XENE): Quarterly 13F Position History
As of Q1 2026, Avoro Capital Advisors LLC reported 5,777,777 shares of XENON PHARMACEUTICALS INC (XENE), worth $336.0M and representing 3.3% of its 13F equity book. Quarter-over-quarter share count change: + 353,333 (+6.5%) . The position first appeared in Q2 2018 and has been disclosed across 32 13F-HR filings in Pactolio's tracked window.
- 5,777,777Shares Held (Latest Filing)
- $336.0MReported Market Value (Latest Filing)
- 3.3%Portfolio Weight (% of 13F Equity Book)
- +353,333Quarter-over-Quarter Share Change
- +$92.9MQuarter-over-Quarter Value Change
- 5,777,777Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 32 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 5,777,777 | +353,333 | +6.5% | $336.0M | 3.3% | $58.1 |
| Q4 2025 | 5,424,444 | +24,444 | +0.5% | $243.1M | 2.4% | $44.8 |
| Q3 2025 | 5,400,000 | 0 | — | $216.8M | 2.8% | $40.1 |
| Q2 2025 | 5,400,000 | 341,666 | -6.0% | $169.0M | 3.0% | $31.3 |
| Q1 2025 | 5,741,666 | +75,000 | +1.3% | $192.6M | 3.0% | $33.5 |
| Q4 2024 | 5,666,666 | 0 | — | $222.1M | 3.1% | $39.2 |
| Q3 2024 | 5,666,666 | 0 | — | $223.1M | 3.3% | $39.4 |
| Q2 2024 | 5,666,666 | 0 | — | $220.9M | 2.9% | $39.0 |
| Q1 2024 | 5,666,666 | 0 | — | $243.9M | 2.8% | $43.0 |
| Q4 2023 | 5,666,666 | +766,666 | +15.6% | $261.0M | 3.6% | $46.1 |
| Q3 2023 | 4,900,000 | 0 | — | $167.4M | 2.6% | $34.2 |
| Q2 2023 | 4,900,000 | 0 | — | $188.7M | 2.6% | $38.5 |
| Q1 2023 | 4,900,000 | 0 | — | $175.4M | 2.6% | $35.8 |
| Q4 2022 | 4,900,000 | 0 | — | $193.2M | 2.9% | $39.4 |
| Q3 2022 | 4,900,000 | 0 | — | $176.9M | 3.3% | $36.1 |
| Q2 2022 | 4,900,000 | 85,000 | -1.7% | $149.1M | 2.9% | $30.4 |
| Q1 2022 | 4,985,000 | 0 | — | $152.4M | 2.8% | $30.6 |
| Q4 2021 | 4,985,000 | +1,335,000 | +36.6% | $155.7M | 2.7% | $31.2 |
| Q3 2021 | 3,650,000 | 0 | — | $55.8M | 0.9% | $15.3 |
| Q2 2021 | 3,650,000 | 0 | — | $68.0M | 1.2% | $18.6 |
| Q1 2021 | 3,650,000 | +850,000 | +30.4% | $65.3M | 1.1% | $17.9 |
| Q4 2020 | 2,800,000 | 0 | — | $43.1M | 0.7% | $15.4 |
| Q3 2020 | 2,800,000 | 0 | — | $31.0M | 0.4% | $11.1 |
| Q2 2020 | 2,800,000 | +28,000 | +1.0% | $35.1M | 0.7% | $12.5 |
| Q1 2020 | 2,772,000 | +372,000 | +15.5% | $31.4M | 1.1% | $11.3 |
| Q4 2019 | 2,400,000 | 0 | — | $31.5M | 0.9% | $13.1 |
| Q3 2019 | 2,400,000 | 0 | — | $21.6M | 0.9% | $9.0 |
| Q2 2019 | 2,400,000 | 0 | — | $23.7M | 0.8% | $9.9 |
| Q1 2019 | 2,400,000 | 0 | — | $24.4M | 1.1% | $10.2 |
| Q4 2018 | 2,400,000 | +32,782 | +1.4% | $15.1M | 0.9% | $6.3 |
| Q3 2018 | 2,367,218 | +1,165,100 | +96.9% | $31.2M | 1.4% | $13.2 |
| Q2 2018 | 1,202,118 | — | — | $11.1M | 0.4% | $9.2 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Avoro Capital Advisors LLC first disclose a XENE position in 13F-HR filings?
Avoro Capital Advisors LLC first reported XENON PHARMACEUTICALS INC (XENE) on its 13F-HR filing for the period ending 2018-06-30 (Q2 2018). The position has appeared on 32 reported quarters within Pactolio's tracked window.
What was Avoro Capital Advisors LLC's most recent quarter-over-quarter share-count change in XENE?
Between Q4 2025 and Q1 2026, Avoro Capital Advisors LLC added 353,333 shares of XENE (+6.5%), bringing the total reported position to 5,777,777 shares at a market value of $336.0M.
Does the implied price-per-share represent Avoro Capital Advisors LLC's cost basis in XENE?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.